Drugs / Intravenous Lipid Emulsion
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02924454 | Sep 2016 → Mar 2017 | hypertensive disorder | Mikkel Bring Christensen | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06988982 | Jun 2025 → Feb 2026 | — | Zagazig University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous lipid emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02924454 ↗ |
| Route | Intravenous | “Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion” NCT02924454 ↗ |